MRES: M2Bio Sciences Unveils Explainer Video Showcasing
Groundbreaking NFTs and
Altcoins for Drug Discovery, Revolutionizing Investment
Access
CAPE TOWN,
SOUTH AFRICA -- July 6, 2023 -- InvestorsHub NewsWire --
Institute of Biomedical Research Corp. (OTC
PINK: MRES) ("Institute of Biomedical Research" or the
"Company"), a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, is pleased to
share the following update:
M2Bio
Sciences, a pioneering biotech company at the forefront of drug
discovery, proudly announces the release of an informative
explainer video elucidating their recent press release regarding
the creation of NFTs and Altcoins for Drug Discovery. This
revolutionary development is set to democratize investing in drug
discovery by offering unprecedented access to potential
investors.
The
captivating explainer video, now available on M2Bio Sciences'
official website and various social media platforms, provides a
comprehensive overview of the groundbreaking concept introduced in
their earlier press release dated June 27th, 2023. Through the
implementation of non-fungible tokens (NFTs) and alternative coins
(Altcoins), M2Bio Sciences aims to transform the way individuals
participate in and benefit from drug discovery
investments.
The
explainer video dives deep into the core principles of M2Bio
Sciences' initiative. By tokenizing drug discovery assets and
creating NFTs, M2Bio Sciences introduces an innovative investment
opportunity that enables individuals from diverse backgrounds to
contribute and partake in the future of healthcare breakthroughs.
Moreover, the introduction of Altcoins within this ecosystem will
empower investors to engage in a decentralized marketplace that
further amplifies the potential for growth and
collaboration.
"We are
thrilled to unveil this explainer video, which aims to educate and
inspire individuals about our novel approach to democratizing
investing in drug discovery," said
Jeff Robinson, CEO of M2Bio Sciences. "Our
vision is to remove barriers and provide everyone with the
opportunity to play an active role in the development of
life-changing pharmaceuticals. By leveraging NFTs and Altcoins, we
are creating a more inclusive and accessible ecosystem for
investors worldwide."
The
explainer video highlights the key advantages of M2Bio Sciences'
pioneering solution. It emphasizes the transparency, security, and
liquidity brought forth by blockchain technology, which ensures
seamless and trustworthy transactions within the drug dM2Bio
Sciences Unveils Explainer Video Showcasing Groundbreaking NFT and
Altcoins for Drug Discovery investment landscape. Furthermore, the
integration of Altcoins fosters a global community of investors,
researchers, and pharmaceutical professionals, collectively working
towards transformative healthcare advancements.
By
demystifying the complex concepts behind NFTs, Altcoins, and their
application in drug discovery, the video ensures that viewers gain
a comprehensive understanding of this groundbreaking investment
opportunity. It
showcases M2Bio Sciences' commitment to driving meaningful change
and promoting financial inclusivity within the pharmaceutical
industry.
To view the
explainer video and learn more about M2Bio Sciences' revolutionary
NFTs and Altcoins for Drug Discovery, please visit the M2Bio
Sciences YouTube channel found here.
M2Bio
Sciences Unveils Explainer Video Showcasing Groundbreaking NFT and
Altcoins for Drug Discovery
M2Bio
Sciences is a pioneering biotech company dedicated to
revolutionizing drug discovery through innovative solutions and
technological advancements. By combining cutting-edge research,
blockchain technology, and decentralized finance, M2Bio Sciences is
empowering individuals globally to participate in the
democratization of drug discovery investment. With a relentless
pursuit of scientific excellence, M2Bio Sciences aims to create
transformative pharmaceuticals and improve healthcare outcomes for
communities worldwide.
About
Institute of Biomedical Research Corp./ DBA M2Bio
Sciences
Institute of Biomedical
Research Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company
(OTC Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333
2148
Find
M2Bio™ on social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe
Harbour Statement - In addition to historical information, this
press release may contain statements that constitute
forward-looking statements within the meaning of the Securities Act
of 1933 and the Securities Exchange Act of 1934, as amended by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include the intent,
belief, or expectations of the Company and members of its
management team with respect to the Company's future business
operations and the assumptions upon which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements. mres